ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm

Heart Valve Diseases Clinical Trial

Official title:

ATS 3f(r) Aortic Bioprosthesis Model 1000

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00657826
• Other study ID #: 2001 Rev. E
• Status: Terminated
• Phase: N/A
• First received: April 4, 2008
• Last updated: June 20, 2016
• Start date: October 2001
• Est. completion date: July 2015

Study information

• Verified date: June 2016
• Source: Medtronic Cardiovascular
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The initial clinical investigation titled "ATS 3f(r) Aortic Bioprosthesis Model 1000 Study," was a prospective, non-randomized, multi-center study designed to evaluate the the safety and effectiveness obtained from 800 patient years using a common clinical protocol. Twenty-three (23) sites internationally and in the United States combined enrolled 405 patients. The objective of the study was to evaluate the safety and effectiveness of the ATS 3f(r) Aortic Bioprosthesis Model 1000 equine pericardial prosthesis in a a patient population undergoing isolated aortic valve replacement of his / her native aortic valve, or replacement of a failed prosthesis with or without concomitant procedures.

Addendum: After receiving PMA approval in October of 2008 of the 21mm-29mm sizes, this IDE was expanded to comply with the conditions set forth in the approval notice. Study Protocol S2001 Rev. E is a continuation of the original protocol, but is only enrolling subjects who require a 19mm ATS 3f(r) Aortic Bioprosthesis, Model 1000 and is described as "A multi-center, non-randomized trial, designed to obtain 800 patient years. Each enrolled patient will be followed for a minimum one year and annually thereafter until size 19mm product approval or study cessation. Preoperative, discharge or 30 days (which ever comes last), 3-6 month, and annual follow-up data are required.

Description:

The patients for whom ATS Medical, Inc., ATS 3f(r) Aortic Bioprosthesis Model 1000 is intended are those patients whose prognosis without surgery for replacement of the diseased natural valve or previous implanted prosthetic valve is unacceptably poor in terms of survival, quality of life, or both, in the opinion of the attending physicians. For this special subset of patients, there are a number of widely accepted prosthetic heart valves in use.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• This patient requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve reconstruction. (The three remaining valves must be of native tissue).

• This patient is sufficiently ill to warrant replacement of his/her diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups.

• This patient is in satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively).

• This patient is geographically stable and willing to return to the implant center for follow-up visits.

• This patient has been adequately informed and consents to his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.

Exclusion Criteria:

• This patient is twenty (20) or less than twenty years of age.

• This patient has a non-cardiac major or progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 12 months.

• This patient is an intravenous drug and/or alcohol abuser.

• This female patient is pregnant (urine HCG test result positive), or lactating.

• This patient presents with active endocarditis.

• This patient presents with congenital bicuspid aortic anatomy.

• This patient has a previously implanted prosthetic valve that is not being replaced by a study valve.

• This patient requires mitral, tricuspid or pulmonic valve replacement.

• This patient is participating in concomitant research studies of investigational products.

• This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heart Valve Diseases

Intervention

Device:
• ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm
Isolated aortic valve replacement with a size 19mm valve

Locations

Country	Name	City	State
Canada	McGill University Health Centre	Montreal	Quebec
United States	Lankenau Institute for Medical Research	Wynnewood	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Cardiovascular

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	NYHA Functional Classification	The NYHA classifications will be analyzed to demonstrate if implanting of the study valve leads to an improvement in this clinical parameter for the patient.	3-6 months, 11-14 months, anuually for a minimum of 800 patient years to support a PMA application to the U.S. FDA	No
Primary	Blood Data	Blood data will be analyzed preoperatively and postoperatively to deomonstrate if implanting of the study valve results in acceptable parameters for SLDH, Haptoglobin, Hematocrit and Reticulocyte parameters. Platelet and white blood cell count will also be analyzed.	3-6 months, 11-14 months, anuually for a minimum of 800 patient years to support a PMA application to the U.S. FDA	Yes
Primary	Cardiovascular Complications	All cardiovascular related complications should be conducted and evaluated according to the STS guidelines. In reporting complications, all cardiovascular related symptoms will be evaluated as to their relation to the valve.	3-6 months, 11-14 months, anuually for a minimum of 800 patient years to support a PMA application to the U.S. FDA	Yes
Primary	Hemodynamic Performance	Assessment of hemodynamic performance shall include analysis of Doppler echocardiographic studies at the early and late postoperative evaluations.	3-6 months, 11-14 months, anuually for a minimum of 800 patient years to support a PMA application to the U.S. FDA	No

External Links

•   Medtronic, Inc. Corporate website